Pharmacology - Mock Test 2

Question 11

Select the indication for which a progestin is used alone without combining with an estrogen

A) Threatened abortion B) Dysfunctional uterine bleeding C) Hormone replacement therapy D) Premenstrual tension

---

No Details

Question 12

Select the progestin preparation for coadministration with estrogen for hormone replacement therapy that does not counteract the beneficial effect of the latter on lipid profile due to lack of androgenic activity

A) Micronized oral progesterone B) Norethindrone C) Lynestrenol D) Medroxyprogesterone acetate

---

No Details

Question 13

Actions of progesterone include the following except

A) Rise in body temperature B) Endometrial proliferation C) Proliferation of acini in mammary gland D) Suppression of cell mediated immunity

---

No Details

Question 14

The distinctive features of desogestrel include the following except

A) It is a prodrug B) It has both strong progestational and strong antiovulatory activities C) It has additional androgenic acitivity D) It does not counteract the beneficial effect of estrogen on lipid profile

---

No Details

Question 15

The 19-Norprogestins differ from progesterone derivatives in that they

A) Have potent antiovulatory activity B) Have no additional androgenic activity C) Have no additional estrogenic activity D) Are preferred for use in endometriosis

---

No Details

Question 16

Progesterone administration

A) Suppresses onset of menstruation B) Induces watery cervical secretion C) Sensitizes the uterus to oxytocin D) Cornifies vaginal epithelium

---

No Details

Question 17

Choose the selective estrogen receptor modulator that is useful in dysfunctional uterine bleeding by acting as estrogen antagonist in endometrium, but does not alter vaginal epithelium or cervical mucus

A) Ormeloxifene B) Tamoxifen C) Centchroman D) Danazol

---

No Details

Question 18

The following is true of raloxifene except

A) It acts as an estrogen agonist in bone B) It exerts estrogen antagonistic action on endometrium C) It increases risk of developing breast cancer D) It can induce/aggravate menopausal hot flushes

---

No Details

Question 19

The following effect(s) of tamoxifen citrate indicate(s) that it possesses tissue specific estrogenic action as well

A) Inhibition of breast cancer cells B) Endometrial proliferation C) Hot flushes in premenopausal women D) All of the above

---

No Details

Question 20

Tamoxifen citrate is used for palliative treatment of carcinoma breast in

A) Premenopausal women B) Postmenopausal women C) Mastectomized patients D) All of the above

---

No Details